A Humoral Mechanism in Anoxic Erythrocytosis

Bonsdorff, Eva; Jalavisto, E

doi:10.1111/j.1748-1716.1948.tb00535.x

Cited by 130 publications

(44 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The existence of this factor was confirmed by Hjort in 1936 [40], Krumdieck in 1943 [50] and Erslev in 1953 [31] but it was Bonsdorf and Jalavisto in 1948 [10] that first used the term erythropoietin. In 1950, Reissman [64] showed that hypoxia stimulated the erythropoietin production and a few years later kidney was reported to be the site of erythropoietin production [45].…”

Section: Historical Backgroundmentioning

confidence: 70%

Erythropoietin in spinal cord injury

Matis

Birbilis

2008

Eur Spine J

View full text Add to dashboard Cite

Spinal cord injury (SCI) is a devastating condition for individual patients and costly for health care systems requiring significant long-term expenditures. Cytokine erythropoietin (EPO) is a glycoprotein mediating cytoprotection in a variety of tissues, including spinal cord, through activation of multiple signaling pathways. It has been reported that EPO exerts its beneficial effects by apoptosis blockage, reduction of inflammation, and restoration of vascular integrity. Neuronal regeneration has been also suggested. In the present review, the pathophysiology of SCI and the properties of endogenous or exogenously administered EPO are briefly described. Moreover, an attempt to present the current traumatic, ischemic and inflammatory animal models that mimic SCI is made. Currently, a clearly effective pharmacological treatment is lacking. It is highlighted that administration of EPO or other recently generated EPO analogues such as asialo-EPO and carbamylated-EPO demonstrate exceptional preclinical characteristics, rendering the evaluation of these tissue-protective agents imperative in human clinical trials.

show abstract

Section: Historical Backgroundmentioning

confidence: 70%

Erythropoietin in spinal cord injury

Matis

Birbilis

2008

Eur Spine J

View full text Add to dashboard Cite

show abstract

“…Against this background and a gathering interest in the effects of hormones, Carnot and Deflandre hypothesized in 1906 that a circulating factor, hemopoietine, was responsible for red cell production and that its concentration in the blood increased in response to anemia or high altitude [12]. The evocative name hemopoietine was replaced in 1948 by the term erythropoietin [13].…”

Section: Epo As a Hormonementioning

confidence: 99%

EPO's Alter Ego: Erythropoietin Has Multiple Actions

Lappin¹,

Maxwell²,

Johnston³

2002

STEM CELLS

116

View full text Add to dashboard Cite

show abstract

“…Bondsdorff and Jalvisto who linked EPO solely with red blood cell production introduced the term "erythropoietin" in 1948 [2]. In 1950s Jacobson and colleagues established that the kidney is the main site of EPO production [3].…”

Section: Introductionmentioning

confidence: 99%

New alternatives for erythropoietin therapy in chronic renal failure

et al. 2007

View full text Add to dashboard Cite

AbstractErythropoietin (EPO) is one of the main cytokines involved in the regulation of erythropoiesis. The main site of EPO production are the kidneys. An altered EPO production leads to pathological conditions such as anemia and polycythaemia. Due to the progressive loss of renal peritubular cells, patients with chronic kidney disease (CKD) have low EPO plasma levels. This decreases erythron stimulation with the direct consequence of developing anemia. Before the introduction in the clinical practice of rHuEpo, in the late 1980s, the only solution for treating this type of anemia were blood transfusions and anabolic steroids. Even rHuEpo has proven to be safe and effective for treatment of anemias, there are some concerns about its cost, the need for frequent parenteral administration, and development of anti-EPO antibodies. These inconveniences prompted the search for novel erythropoiesis stimulating agents. Different strategies lead to isolation or chemical synthesis of such agents as darbepoetin alfa and EPO mimetics. In this review, we present some general aspects of EPO biology, with emphasis on chronic renal failure, and expose some of the alternatives to EPO used for anemia correction.

show abstract

A Humoral Mechanism in Anoxic Erythrocytosis

Cited by 130 publications

References 14 publications

Erythropoietin in spinal cord injury

Erythropoietin in spinal cord injury

EPO's Alter Ego: Erythropoietin Has Multiple Actions

New alternatives for erythropoietin therapy in chronic renal failure

Contact Info

Product

Resources

About